Galmed Pharmaceuticals (NASDAQ:GLMD) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Galmed Pharmaceuticals (NASDAQ:GLMD) to a sell rating in a report published on Saturday morning.

Separately, Maxim Group reaffirmed a “hold” rating on shares of Galmed Pharmaceuticals in a research note on Friday, April 4th.

Galmed Pharmaceuticals Trading Down 1.4%

GLMD opened at $1.39 on Friday. Galmed Pharmaceuticals has a 1-year low of $1.15 and a 1-year high of $23.80. The company has a market cap of $2.30 million, a P/E ratio of -0.08 and a beta of 0.49. The company has a fifty day moving average price of $1.45 and a two-hundred day moving average price of $2.28.

Galmed Pharmaceuticals (NASDAQ:GLMD) last posted its quarterly earnings results on Thursday, May 22nd. The biopharmaceutical company reported ($0.62) earnings per share for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned about 3.97% of Galmed Pharmaceuticals at the end of the most recent reporting period. 76.14% of the stock is currently owned by institutional investors and hedge funds.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.